These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 22469324)

  • 1. Varenicline.
    Kassem MG; Al Hossaini AM
    Profiles Drug Subst Excip Relat Methodol; 2012; 37():389-411. PubMed ID: 22469324
    [No Abstract]   [Full Text] [Related]  

  • 2. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
    Coe JW; Brooks PR; Vetelino MG; Wirtz MC; Arnold EP; Huang J; Sands SB; Davis TI; Lebel LA; Fox CB; Shrikhande A; Heym JH; Schaeffer E; Rollema H; Lu Y; Mansbach RS; Chambers LK; Rovetti CC; Schulz DW; Tingley FD; O'Neill BT
    J Med Chem; 2005 May; 48(10):3474-7. PubMed ID: 15887955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecule of the Month. Varenicline tartrate.
    Drug News Perspect; 2006 Apr; 19(3):162. PubMed ID: 16804568
    [No Abstract]   [Full Text] [Related]  

  • 4. Practical implementation of varenicline as an aid to smoking cessation in clinical practice.
    Tonstad S
    Pneumologia; 2009; 58(3):167-74. PubMed ID: 19817313
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolism and disposition of varenicline, a selective alpha4beta2 acetylcholine receptor partial agonist, in vivo and in vitro.
    Obach RS; Reed-Hagen AE; Krueger SS; Obach BJ; O'Connell TN; Zandi KS; Miller S; Coe JW
    Drug Metab Dispos; 2006 Jan; 34(1):121-30. PubMed ID: 16221753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varenicline in smoking cessation.
    Tonstad S; Rollema H
    Expert Rev Respir Med; 2010 Jun; 4(3):291-9. PubMed ID: 20524911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
    Mihalak KB; Carroll FI; Luetje CW
    Mol Pharmacol; 2006 Sep; 70(3):801-5. PubMed ID: 16766716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single- and multiple-dose pharmacokinetics of the selective nicotinic receptor partial agonist, varenicline, in healthy Japanese adult smokers.
    Kikkawa H; Maruyama N; Fujimoto Y; Hasunuma T
    J Clin Pharmacol; 2011 Apr; 51(4):527-37. PubMed ID: 20551220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Smoking cessation: an overview of treatment options with a focus on varenicline.
    Stack NM
    Pharmacotherapy; 2007 Nov; 27(11):1550-7. PubMed ID: 17963463
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varenicline for smoking cessation.
    Tonstad S
    Expert Rev Neurother; 2007 Feb; 7(2):121-7. PubMed ID: 17286546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A brief review of pharmacotherapeutic treatment options in smoking cessation: bupropion versus varenicline.
    Johnson TS
    J Am Acad Nurse Pract; 2010 Oct; 22(10):557-63. PubMed ID: 21040090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quitting smoking without a psychotic break: the potential link between nicotinic acetylcholine receptor partial agonists and neuropsychiatric adverse events.
    O'Malley P
    Clin Nurse Spec; 2009; 23(1):13-5. PubMed ID: 19098509
    [No Abstract]   [Full Text] [Related]  

  • 13. Varenicline reduced smoking behaviour in a mentally ill person.
    Ochoa EL
    J Psychopharmacol; 2009 May; 23(3):340-1. PubMed ID: 18562426
    [No Abstract]   [Full Text] [Related]  

  • 14. Utilization management for smoking cessation pharmacotherapy: varenicline rejected claims analysis.
    Zeng F; Chen CI; Mastey V; Zou KH; Harnett J; Patel BV
    Am J Manag Care; 2010 Sep; 16(9):667-74. PubMed ID: 20873954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of late-life onset mania during Varenicline assisted smoking cessation.
    Francois D; Odom A; Kotbi N
    Int J Geriatr Psychiatry; 2011 Jun; 26(6):658-9. PubMed ID: 21480382
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and safety of varenicline for smoking cessation.
    Hays JT; Ebbert JO; Sood A
    Am J Med; 2008 Apr; 121(4 Suppl 1):S32-42. PubMed ID: 18342165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of allopurinol on smoking.
    Esparza-Martín N; Suria-González S; García-Cantón C; Ramírez-Puga A; Guerra-Rodríguez R; Checa-Andrés MD
    Nefrologia; 2013 Nov; 33(6):858-60. PubMed ID: 24241378
    [No Abstract]   [Full Text] [Related]  

  • 18. [New drugs; varenicline].
    van Bronswijk H; Dubois EA; Zitman FG; Cohen AF
    Ned Tijdschr Geneeskd; 2007 Nov; 151(45):2503-4. PubMed ID: 18062594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of varenicline (clinical ramifications): electron transfer and oxidative stress.
    Kovacic P
    Med Hypotheses; 2007; 68(5):1184-5. PubMed ID: 17127014
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.